PARKINSON : TOWARDS A CURE FOR TOMORROW
Current therapies are based on dopaminergic signaling, a therapeutic strategy with demonstrated efficacy, but with serious limits. Levodopa and dopaminergic compounds slowly lose their efficacy over time. Furthermore, they only target part of the motor symptoms of the disease, leaving untreated motor symptoms such as posture and gait disorders, as well as non-motor symptoms, including cognition, mood or digestive disorders. Finally, current therapies are plagued with severe complications, ranging from compulsive disorders to levodopa-induced dyskinesia and motor fluctuations. Therefore, innovation is expected to bring solutions able to change patients’ lives, by increasing the efficacy of the current therapies, and addressing these unmet medical needs.
CleveXel is proud to collaborate for his clinical study with Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute), an international brain and spinal cord research center specialized in Parkinson’s disease and Movement Disorders.
Clinical trial design, assessment of projects fit to current medical needs benefits from discussions with our network of experts, including Christopher Goetz, Fabrizio Stocchi, Olivier Rascol, Jean-Christophe Corvol and Laura Bossi-Régnier.
Parkinson’s Disease: a challenge for modern medicine